$BSVN

Bank7 Corp. (BSVN): Entry into a Material Definitive Agreement

Bank7 Corp. (BSVN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ef20077345_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 Execution Version STOCK PURCHASE AGREEMENT by and between BANK7 CORP. and MCA FINANCIAL GROUP, LTD. Dated as of July 1, 2026 TABLE OF CONTENTS Page ARTICLE 1 Interpretation Section 1.01. Definitions 2 Section 1.02. Currency 7

Original reporting
Published Jul 2, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$BSVN
Neutral
medium confidence
Mentioned
$BSVN
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BSVNNeutralMed
01

Why it matters

If the deal closes, Bank7 could gain exposure to Century/its bank subsidiary; however, closing is subject to conditions, consents/approvals, and court-ordered sale mechanics described in the agreement.

02

Market read

This is a primary-source deal disclosure for BSVN, creating near-term uncertainty around closing and deal economics that can drive trading around the filing and subsequent updates.

03

What to watch

Key trading drivers—purchase price/consideration, size of the acquired stake, regulatory approval path, and any break-up/termination economics—are not included in the provided excerpt, so traders should wait for the full exhibit details.

Relevance 6/10Novelty 6/10Timing: after-hours/filing today (2026-07-02) for a pending receivership stock purchase agreement

Background

The 8-K states Bank7 Corp. entered a material definitive stock purchase agreement dated July 1, 2026, involving a court-appointed receiver and a receivership estate tied to Century Financial Services Corporation’s shares.

Company-level read

Ticker impact

$BSVNNeutralMedium confidence
Context

Bank7 Corp. entered a material definitive stock purchase agreement disclosed in an SEC 8-K, signaling a pending acquisition/transaction tied to a receivership sale.

Expected impact

Moderate two-sided reaction risk around deal terms/closing odds; direction depends on consideration size and regulatory/closing conditions not shown in the excerpt.

Evidence & confidence

This is a primary SEC 8-K disclosure of a material definitive agreement, but the provided text is largely boilerplate and does not include key deal economics or closing certainty.

Market effects

Could affect regional bank holding company M&A/receivership resolution sentiment, but no broader sector datapoints are provided.

Transaction is tied to a specific receivership estate and state-bank holding company; limited spillover beyond the involved markets.

Low; this is a localized US banking/receivership transaction with no cross-border elements in the excerpt.

Counterpoint

The agreement may not translate into closing (regulatory approvals, court process, or conditions), so the market may discount the news until concrete economics and approval milestones are released.

Key entities

  • Bank7 Corp.

    Purchaser entering the material definitive stock purchase agreement disclosed on SEC Form 8-K.

  • MCA Financial Group, Ltd.

    Court-appointed receiver party to the stock purchase agreement.

  • Century Financial Services Corporation

    Receivership estate whose common stock shares are the subject of the sale agreement.

Related articles

$BSVNMed

Bank7 (BSVN) Q2 2026 Earnings Call Transcript

Bank7 Corp. (BSVN) reported Q2 2026 net income of $8.35 million, down 24.8% from $11.11 million, and diluted EPS of $0.87 versus $1.16. Total loans rose 6.7% to $1.60 billion and total assets grew 4.3% to $1.91 billion. Management guided Q3 expenses of $9.5 million to $9.7 million and core NIM of 4.45% to 4.53%.

$BSVNMed

Bank7 Corp. Q2 2026 Earnings Call Summary

Bank7 Corp. reported a $3.7 million net gain from exiting its oil and gas investment and said IT material-weakness remediation and related non-recurring costs raised operating expenses. It reiterated mid-single-digit full-year loan growth guidance, expects Q3 expenses of $9.5 million to $9.7 million, and guided core NIM at 4.45% to 4.53%. The bank is pursuing a 71% stake in Century via a court-monitored auction.

$BSVNMed

Bank7 Corp. (BSVN): Results of Operations and Financial Condition

Bank7 Corp. (BSVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20078094_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE: Bank7 Corp. Announces Q2 2026 Earnings Oklahoma City, July 16, 2026 – Bank7 Corp. (NASDAQ: BSVN) ("the Company"), the parent company of Oklahoma City-based Bank7 (the "Bank"), today reported unaudite

$BSVNMedAI 8/10

Bank7 Corp. Announces Agreement to Acquire Controlling Interest in Century Financial Services Corporation

Bank7 Corp. (NASDAQ: BSVN) said it signed a definitive stock purchase agreement to acquire about a 71% controlling stake in Century Financial Services Corp., the holding company for Century Bank. The shares are sold via a court-supervised process; Bank7 will act as stalking-horse bidder. Century Bank had $1.35B assets and $1.22B deposits as of Mar. 31, 2026. Closing is expected in Q3.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.